RFM
OTLK icon

Royal Fund Management’s Outlook Therapeutics OTLK Stock Holding History

Royal Fund Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75K Buy
+47,200
New +$29.3K 0.01% 279

Other funds holding OTLK

GWM
Gilpin Wealth Management Denver, Colorado $145M AUM
WMP
Wealth Management Partners Tucson, Arizona $425M AUM 60.71% 1-Year Est. Return
CKAIS
Christensen King & Associates Investment Services Richland, Washington $252M AUM 20.51% 1-Year Est. Return
FCC
Flower City Capital Pittsford, New York $227M AUM 23.31% 1-Year Est. Return
OFS
Orrstown Financial Services Harrisburg, Pennsylvania $674M AUM 23.23% 1-Year Est. Return
FTWA
Fifth Third Wealth Advisors Cincinnati, Ohio $3.58B AUM 34.55% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Royal Fund Management's OTLK Position: Q2 2026 in Review

Royal Fund Management opened a new position in Outlook Therapeutics (OTLK) in Q2 2026: 47,200 shares worth $75K. The stake represents 0.01% of the portfolio and ranks #279 among its holdings.

13 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Royal Fund Management held 47,200 shares of Outlook Therapeutics worth $75K as of Q2 2026.
  • Outlook Therapeutics was a new Royal Fund Management position in Q2 2026.
  • Outlook Therapeutics made up 0.01% of Royal Fund Management's portfolio in Q2 2026, its #279 holding.
  • 13 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Royal Fund Management's 13F filing for Q2 2026, filed 20 Jul 2026.